- Policy
- HIRA completes selective reimbursement listing
- by Lee, Hye-Kyung Dec 4, 2020 05:54am
- To reinforce the National Health Insurance (NHI) coverage, the South Korean health authority granted selective reimbursement on 16 out of 23 anticancer therapies without the healthcare reimbursement standard or left as a non-reimbursement with 100-percent copayment rate. According to the list of anticancer treatments with selective reimburse
- Company
- The liver cancer treatment market is fluctuating
- by Kim, Jin-Gu Dec 4, 2020 05:53am
- The liver cancer treatment market is fluctuating greatly. Sales of Nexavar (Sorafenib), which occupied an absolute position in the market, declined significantly, while sales of Lenvima (Lenvatinib) increased. Hanmi's Soranib, which succeeded in overcoming Nexavar's patent, is scheduled to be released, and attention is focused on whethe
- Company
- Sanofi's multiple myeloma tx Sarclisa was approved in Korea
- by Dec 4, 2020 05:53am
- Sanofi-Aventis Korea (CEO Kyung-Eun Bae) announced on the 2nd that its relapsed and refractory multiple myeloma treatment Sarclisa (Isatuximab-irfc) was approval from the MFDS on the 1st. Sarclisa was previously approved as a combination therapy with Pomalidomide and Dexamethasone in patients with multiple myeloma who received more than on
- Company
- Joint venture Akijen withdrew in 6 years
- by An, Kyung-Jin Dec 4, 2020 05:53am
- Akijen, a joint venture established by Samsung Biologics and multinational pharmaceutical company AstraZeneca, is going through the process of rearranging the business in six years. According to Samsung Biologics' quarterly report submitted to the Financial Supervisory Service on the 2nd, the company decided to stop research and developme
- Company
- Rob Kempton inaugurated as the new president of GSK
- by Dec 3, 2020 11:32am
- GSK announced on the 30th that it will appoint Rob Kempton as the president of GSK's Korean subsidiary on Dec 1st. New president Rob Kempton is a healthcare professional with over 20 years of pharmaceutical experience in the US, UK and Asia. After joining GSK in 2013, he was in charge of sales management in the United States of Viiv Health
- Policy
- Life expectancy regulations for RSA drugs will be maintained
- by Lee, Jeong-Hwan Dec 3, 2020 06:01am
- The MOHW has announced that it will not change the two-year life expectancy rule applied to the 'risk sharing system (RSA)' applied to high-priced new drugs such as the latest anticancer drugs and rare disease treatment drugs. This regulation was established by referring to similar overseas systems such as the UK and Australia, and it is b
- Company
- Celltrion completes acquisition of Takeda APAC products
- by An, Kyung-Jin Dec 3, 2020 06:00am
- On Dec. 1, Celltrion announced it completed the acquisition for the Asia-Pacific market products from a multinational pharmaceutical company Takeda Pharmaceutical Company (“Takeda”). In last June, the South Korean company signed a deal to take over the rights to Takeda’s 18 Primary Care product assets from the Asia-Pacific markets for
- Policy
- 16 new drugs listed including Kisqali, Verzenio & Ibrance
- by Kim, Jung-Ju Dec 3, 2020 06:00am
- A total of 16 major new drugs for which insurance benefit coverage was initiated this year were counted. A total of 4 drugs have lowered the burden on patients due to lower benefit standards. Regardless of the estimated size of insurance finance, the tendency to expand flexible coverage was established according to social importance and patient
- Company
- Sanofi cut from Innovative Company list first time in 6 year
- by Eo, Yun-Ho Dec 2, 2020 06:06am
- A multinational pharmaceutical company Sanofi-Aventis Korea has been cut from the list of Innovative Pharmaceutical Companies for the first time in six years. South Korea’s Ministry of Health and Welfare (MOHW, Minister Park Neung-hoo) convened a second Pharmaceutical Industry Fostering and Support Committee meeting for the year and fin
- Company
- Hanmi's Xoterna wins first trial in patent dispute
- by Kim, Jin-Gu Dec 2, 2020 06:06am
- Hanmi won the patent dispute between Hanmi and Novartis over Xoterna (Indacaterol/Glycopyrronium), a treatment for COPD (chronic obstructive pulmonary disease). The Intellectual Property Trial and Appeal Board recently issued a trial decision for partial approval and dismissal in a trial for invalidation of a patent for the Xoterna partia
